Georgia Erbez - 01 Jul 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Role: Director
Signature: /s/ Georgia Erbez; By: Mary Christina Thomson, Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 01 Jul 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Jul 2022, 16:25:41 UTC
Previous filing: 01 Feb 2022
Next filing: 22 Feb 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Stock Option (right to buy)	Disposed to Issuer	$0	-18,000	-100%	$0.000000^*	0	01 Jul 2022	Common Stock	18,000	$17.76	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Georgia Erbez is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.
F2	Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.